Results 71 to 80 of about 50,773 (265)

From Inflammatory Bowel Disease to Cancer: Gut Microbiota–Immune Microenvironment Crosstalk and Natural Product‐Based Therapeutic Opportunities

Cancer Nexus, EarlyView.
ABSTRACT Inflammatory bowel disease (IBD), primarily Crohn's disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract and an important risk factor for IBD‐associated cancer. Increasing evidence suggests that gut microbiota dysbiosis, epithelial barrier dysfunction, and immune microenvironment remodeling
Xue Zhang, Chongchong Gao, Rui Jiang, Zijian Wu, Jian Bai   +4 more
wiley   +1 more source

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Tofacitinib for the Treatment of Psoriasiform Dermatitis Caused by IL-17 Inhibitors: A Case Report

Journal of Inflammation Research, 2023
Nan Luo, Lingyuan Zhong, Nana Luo, Qiuyue Wang, Tianhao Li, Pingsheng Hao Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of ChinaCorrespondence: Pingsheng Hao; Tianhao Li, Department ...
Luo N, Zhong L, Luo N, Wang Q, Li T, Hao P   +5 more
doaj  

Janus kinase inhibitors in immunoinflammatory rheumatic diseases

Terapevticheskii arkhiv, 2022
Despite great advances in the diagnosis and treatment of immunoinflammatory rheumatic diseases, which have led to a significant improvement in the prognosis in many patients, the fundamental medical problems of this pathology the restoration of the quality of life and the reduction of mortality to the population level are far from being resolved ...
openaire   +3 more sources

Ruxolitinib Pharmacokinetics and Exposure–Toxicity Relationship in Hematologic Malignancies and Immune‐Mediated Diseases: A Prospective Observational Study

Clinical Pharmacology &Therapeutics, EarlyView.
Ruxolitinib pharmacokinetics (PK) has been characterized in clinical trials but remains poorly documented in real‐world practice. This project aimed to investigate ruxolitinib PK in routine clinical practice, identify factors driving its variability, and explore exposure–response relationships to assess the potential role of therapeutic drug monitoring.
Jérémie Tachet, Sara C. Meyer, Francesco Grandoni, Emmanuel Haefliger, Monika Nagy‐Hulliger, Jörg P. Halter, Jakob R. Passweg, David Haefliger, Carine Bardinet, Laurent A. Decosterd, Monia Guidi, François R. Girardin   +11 more
wiley   +1 more source

Successful treatment of recalcitrant follicular lichen planus (lichen planopilaris) with the topical JAK 1/2 inhibitor ruxolitinib

JEADV Clinical Practice
We report the successful treatment of a patient with refractory follicular lichen planus (LP) with topical ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, which resulted in significant improvement of lesional skin within 1 month of daily use.
Tanja Fetter, Dagmar Wilsmann‐Theis, Luka deVos‐Hillebrand, Natalija Novak, Joerg Wenzel   +4 more
doaj   +1 more source

Janus Kinase Inhibitors in Dermatology

Indian Journal of Drugs in Dermatology, 2019
Janus kinase (JAK) inhibitors are a new addition in the armamentarium of drugs in the treatment of autoimmune dermatoses. They have proven to be valuable in treating a variety of inflammatory dermatoses with lesser side effects compared to their biological counterparts. This review throws light on JAK inhibitors and their role
openaire   +1 more source

RORγt‐APCs: The New Masters of Oral Tolerance

Barrier Immunity, EarlyView.
ABSTRACT Oral tolerance is defined by the hypo‐responsiveness of our body to fed antigens, and its failure can lead to immune‐mediated diseases, such as allergy, chronic inflammation and autoimmune diseases. Decades of research have demonstrated that antigen‐presenting cells (APCs) promote oral tolerance by inducing regulatory T cells (Tregs) and/or ...
Thierry Gauthier, WanJun Chen
wiley   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Treatment advances in Vitiligo: An Updated Review

Dermatology Practical & Conceptual
Introduction Vitiligo is a common disorder of depigmentation caused by the progressive destruction of melanocytes that affects the skin, hair, and mucous membranes, clinically presenting as depigmented macules and leukotrichia.
Ishrat Binti Ismail, Yasmeen Jabeen Bhat, Mohd Shurjeel ul Islam   +2 more
doaj   +1 more source